Article Text

Download PDFPDF

495 BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo
  1. Mary van Helden1,
  2. Roel Arends1,
  3. Seline Zwarthoff1,
  4. Monique van der Vleuten1,
  5. Marc Paradé1,
  6. Karin de Laat-Arts1,
  7. Hugo Olsman2,
  8. Ellen Mattaar1,
  9. Dirk Glaudemans1,
  10. Daniëlle van Wijk1,
  11. Lilian Driessen-Engels1,
  12. Inge Reinieren-Beeren1,
  13. Paul Boersema1,
  14. Eva Hanckmann1,
  15. Gerard Rouwendal1,
  16. Ruud Ubink1,
  17. Miranda van der Lee1,
  18. Gijs Verheijden1,
  19. Wim Dokter1 and
  20. Timo van den Berg1
  1. 1Byondis, Nijmegen, Netherlands
  2. 2Sanquin Research, Amsterdam, Netherlands


Background Preclinical data have established CD47-SIRPα interactions as a myeloid immune checkpoint in cancer, which is corroborated by preliminary evidence from the first clinical studies with CD47 blockers.

Methods However, the ubiquitously expressed CD47 mediates functional interactions with other ligands as well, and therefore targeting of the primarily myeloid cell-restricted inhibitory immunoreceptor SIRPα may represent a better strategy.

Results Here, we present preclinical results on a novel clinical candidate, BYON4228. BYON4228 is an antibody directed against SIRPa and recognizes both of the common allelic variants of human SIRPα which maximizes its potential clinical application in the broad human population. Notably, in contrast to several other anti-SIRPα antibodies in development, BYON4228 does not recognize the closely related T cell-expressed SIRPγ that has been reported to mediate interactions with CD47 as well, which are known to be instrumental in T cell extravasation and activation. BYON4228 binds to the N-terminal part of SIRPα and its epitope overlaps with the CD47-binding site. BYON4228 therefore prevents binding of CD47 to SIRPα and thus blocks inhibitory signaling through the CD47-SIRPα axis. Functional studies show that BYON4228 potentiates both macrophage- and neutrophil-mediated elimination of hematologic and solid cancer cells in vitro in the presence of several different tumor targeting antibodies like trastuzumab, rituximab, daratumumab and cetuximab, illustrating the broad potential clinical benefit and application of BYON4228. BYON4228 enhanced the efficacy of rituximab treatment in vivo when administered to human Non-Hodgkin lymphoma (NHL)-engrafted transgenic mice with a selective expression of huSIRPαBIT on myeloid cells (huSIRPαBIT-scid mice). Single intravenous infusion of up to 100 mg/kg BYON4228 to male and female cynomolgus monkeys was well tolerated and did not elicit any adverse effects.

Conclusions Collectively, this defines BYON4228 as a pan-allelic anti-SIRPα antibody without T cell SIRPγ recognition that promotes the destruction of antibody-opsonized cancer cells. Clinical studies are planned to start in 2022.

Ethics Approval Appropriate ethics approvals were present before commencing studies in vivo.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.